Cover Story Pharma's Top 50: Our 6th Annual Report
Contributing WriterThis year's list of the top 50-ranked pharma companies includes movers, mainstays, mergers, and more.
A new Pharm Exec feature: Meet the teams behind some of the top pharma ad campaigns of 2004.
Eisai's New Leadership
US president and COO Lonnel Coats, and chairman and CEO Hajime Shimizu, talk about their first year at the helm of Eisai.
Richard Gliklich, MD
In the fast-growing world of post-approval studies, competition for research sites is heating up. Here's how to play the game.
Elephant or Specialist?
Apollo Consulting Group
Medicare wants to create new market forces to drive down costs. How should you respond? First you need to know what you are.
Beyond the Call
Stan Zehner and Beth Ann Pelegan
Sure, an integrated call center system can make phone operators' jobs easier. But there's a much better reason to use one.
It's All About Immunity
After 9/11, San Diego-based Hollis-Eden discovered a new mission: developing an FDA-approved treatment for acute radiation sickness.
Special Report: Spend Trends
Analysts predict that the booming DTC advertising market is about to shift from branded campaigns to disease-awareness efforts.
Leading Indicators News Giuliani's research group pokes holes in drug importation plans " WHO calls for international treaty to combat counterfeiting of drugs " FDA bans inhalers that use chlorofluorocarbon propellants " Pfizer gets warned about Zyrtec ads " Part B: the new Part D
Data Americans fail compliance test " Potential problems with Part B price controls " Mental health meds are in high demand
Thought Leaders Lisa Drakeman, Genmab's CEO, on the art of biotech dealmaking.
Washington Report Some think recent withdrawal actions signal a more risk-averse stance at FDA; cynics say it's just another swing of the regulatory pendulum.
Global Report Government officials in the UK are calling for tougher regulations of pharma.
Leadership Two perspectives on achieving work/life balance.
Sander Flaum Flaum Partners
Jonathon Flaum WriteMind Communications
Legal ForumPatent rulings have limited the use of costly research tools. Researchers are coming up with answers.